VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction

Journal of Molecular Neuroscience

Volumn 52, Issue 1, 2014, Pages 10-17

  Carrión, Mar ^a   Juarranz, Yasmina ^a   Seoane, Iria V ^a   Martínez, Carmen ^a   González Álvaro, Isidoro ^b   Pablos, José Luis ^c   Gutiérrez Cañas, Irene ^a   Gomariz, Rosa P ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

IL 22R1; MMP 1; Rheumatic diseases; S100A8 A9 alarmins; Synovial fibroblast; Vasoactive intestinal peptide

Indexed keywords

CALGRANULIN A; CALGRANULIN B; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR1; INTERLEUKIN RECEPTOR; INTERSTITIAL COLLAGENASE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT DESTRUCTION; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVITIS; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; CALGRANULIN A; CELLS, CULTURED; FIBROBLASTS; HUMANS; INTERLEUKINS; JOINT CAPSULE; MATRIX METALLOPROTEINASE 1; OSTEOARTHRITIS; RECEPTORS, INTERLEUKIN; SYNOVITIS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84895074555     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0177-3     Document Type: Article

References (41)

1. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M et al (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid model of Crohn's disease. Gastroenterology 124:961-971
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
3. Arranz A, Gutiérrez-Cañas I, Carrión M, Juarranz Y, Pablos JL, Martínez C et al (2008) VIP reverses the expression profiling of TLR4-stimulated signalling pathway in rheumatoid arthritis synovial fibroblasts. Mol Immunol 45:3065-3073
4. Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233:233-255
5. Bottini N, Firestein GS (2013) Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 9:24-33
6. Calich AL, Domiciano DS, Fuller R (2010) Osteoarthritis: can anti-cytokine therapy play a role in treatment. Clin Rheumatol 29(17):451-455
7. Carrión M, Juarranz Y, Pérez-García S, Jimeno R, Pablos JL, Gomariz RP et al (2011) RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum 63:1626-1636
8. Carrión M., Juarranz Y., Martínez C., Gonzalez-Alvaro I., L. Pablos J.L., Gutiérrez-Canas I. et al. (2013a) IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology. doi: 10.1093/rheumatology/ket315
9. Carrión M, Pérez-García S, Jimeno R, Juarranz Y, González-Álvaro I, Pablos JL et al (2013b) Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and -23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: immunomodulation by vasoactive intestinal Peptide. Neuroimmunomodulation 20:274-284
10. da Rocha LF, Jr DÂL, Dantas AT, Mariz HA, Pitta IR, Galdino SL et al (2012) Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol 39:1320-1325
11. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7:563-568
12. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356-361
13. Grevers LC, de Vries TJ, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ et al (2011) S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4. Arthritis Rheum 63:1365-1375
14. Gutiérrez-Cañas I, Juarranz Y, Santiago B, Arranz A, Martinez C, Galindo M et al (2006) VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology 45:527-532
15. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K et al (2005) Expression of IL-22 in rheumatoid arthritis. Arthritis Rheum 52:1037-1046
16. Jimeno R, Gomariz RP, Gutiérrez-Cañas I, Martínez C, Juarranz Y, Leceta J (2010) New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 88:734-745
17. Juarranz MG, Santiago B, Torroba M, Gutierrez-Cañas I, Palao G, Galindo M et al (2004) Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 43:416-422
18. Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Cañas I, Rosignoli F et al (2005) Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. J Arthritis Res Ther 7:R1034-R1045
19. Juarranz Y, Gutiérrez-Cañas I, Arranz A, Martínez C, Abad C, Leceta J et al (2006) VIP decreases TLR4 expression induced by LPS and TNFα treatment in human synovial fibroblasts. Ann NY Acad Sci 1070:359-364
20. Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP (2008) Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 58:1086-1095
21. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O (2003) Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 48:1676-1685
22. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H (2011) Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 7:33-42
23. Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ et al (2012) IL-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum 64:1015-1023
24. Leipe J, Schramm MA, Grunke M, Baeuerle M, Dechant C, Nigg AP et al (2011) Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 70:1453-1457
25. Li H, Mei Y, Wang Y, Xu L (2006) Vasoactive intestinal peptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 26:430-437
26. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP et al (2006) Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 65:195-200
27. Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N et al (2002) Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 99:1053-1058
28. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429-442
29. Mitra A, Raychaudhuri S, Raychaudhiri SP (2012) Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther 14:R65
30. Murphy G, Nagase H (2008) Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 4:128-135
31. Neumann E, Lefèvre S, Zimmermann B, Gay S, Müller-Ladner U (2010) Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med 16:458-468
32. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ et al (2007) Moderate pulmonary arterial hypertension in the male mice lacking the vasoactive intestinal peptide gene. Circulation 115:1260-1268
33. Scanzello CR, Goldring SR (2012) The role of synovitis in osteoarthritis pathogenesis. Bone 51:249-257
34. Schelbergen RF, Blom AB, van den Bosch MH, Slöetjes A, Abdollahi-Roodsaz S, Schreurs BW et al (2012) Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum 64:1477-1487
35. Scott DL (2012) Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 91:30-43
36. Sellam J, Berenbaum F (2010) The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 6:625-635
37. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H et al (2006) The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid artritis. Arthritis Res Ther 8:R69
38. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T et al (2006) Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291:L880-L886
39. Vacas E, Arenas MI, Muñoz-Moreno L, Bajo AM, Sánchez-Chapado M, Prieto JC et al (2013) Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice. Cancer Lett 336:196-203
40. van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T et al (2008) Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 67:1750-1758
41. van Lent PL, Blom AB, Schelbergen RF, Slöetjes A, Lafeber FP, Lems WF et al (2012) Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum 64:1466-1476